MedTrace Logo

Detemir: Role in Type 1 Diabetes

NCT00564395 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-07-17

Study results available
· View outcomes & findings →

Summary

Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart). It is hypothesized that there is no difference in the patterns of blood sugars when detemir is given in the same syringe or in separate syringes with rapid acting insulin.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Insulin Detemir mixed with RAI injection

Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection

DRUG

Insulin Detemir and RAI injection

Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection

Sponsors & Collaborators

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Rubina A Heptulla, MD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
10 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-12-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00564395 on ClinicalTrials.gov